XWPharma

Discovery and development of CNS therapeutics

Category
CNS
Location
Wuhan, China
Website
Visit website

About the company

Developing innovative medicines for neurological and psychiatric disorders. Lead program, XW10508, is a Ph2 oral NMDA antagonist for treatment-resistant depression with a differentiated adverse events profile